(267 days)
No
The 510(k) summary describes a hip implant (stem) and its indications for use, material, and testing. There is no mention of software, algorithms, image processing, AI, or ML. The performance studies focus on mechanical and material properties, not algorithmic performance.
Yes
The device is a hip stem used in total or partial hip replacement, which are procedures aimed at alleviating pain and restoring function due to various conditions like arthritis, necrosis, or fractures. This directly addresses health issues and aims to improve a patient's physical well-being, thus fitting the definition of a therapeutic device.
No
The device description clearly states it is a "hip stem" designed for "total hip replacement or hip arthroplasty," which are surgical procedures, not diagnostic activities. The intended use also lists conditions that the device treats rather than diagnoses.
No
The device description explicitly states it is a physical hip stem manufactured from titanium alloy with a hydroxyapatite coating.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The intended use describes the device as a hip replacement or hemi-arthroplasty for treating various conditions affecting the hip joint. This is a surgical implant, not a test performed on biological samples.
- Device Description: The description details the physical characteristics of a hip stem, including its material, coating, and design. This is consistent with a medical device intended for implantation.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body to provide information for diagnosis, monitoring, or compatibility.
Therefore, this device falls under the category of a surgical implant, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Total hip replacement or hip arthroplasty is indicated in the following conditions:
- A severely painful and/or disabled joint from osteoarthritis, traumatoid arthritis, or congenital hip dysplasia.
- Avascular necrosis of the femoral head.
- Acute traumatic fracture of the femoral head or neck.
- Failed previous hip surgery including joint reconstruction, arthrodesis, hemi-arthroplasty, surface replacement arthroplasty, or total hip replacement.
- Certain cases of ankylosis.
Partial hip replacement or hip hemi-arthroplasty is indicated in the following conditions:
- Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation.
- Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation.
- Avascular necrosis of the femoral head.
- Non-union of femoral neck fractures.
- Certain high subcapital and femoral neck fractures in the elderly.
- Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement.
- Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemi-arthroplasty.
HA coated stems of the Corail Hip System are indicated for cementless use only.
Product codes (comma separated list FDA assigned to the subject device)
LZO, MEH, KWL, KWY
Device Description
The DePuy Corail AMT hip stems are manufactured from forged titanium alloy (Ti6Al4V) and plasma-sprayed with a hydroxyapatite (HA) coating for bone fixation. The stem consists of a wide range of stem neck designs and sizes allowing an accurate anatomical match for each patient. Corail AMT stems are available with or without a collar, with various neck angles, and with various neck offsets. The stems are compatible with both unipolar and bipolar heads intended for hip hemi-arthroplasty and with modular femoral heads intended for total hip arthroplasty.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Hip
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical tests were conducted for determination of substantial equivalence:
- Neck fatigue testing in accordance with ISO 7206-6:1992
- Distal fatigue testing in accordance with ISO 7206-4:2010
- Validation of taper dimension
- Validation of taper to head and neck to head dimension
- Range of motion in accordance with ISO 21535:2007
- Pyrogenicity testing using the Bacterial Endotoxin Testing (BET) method as specified in ANSI/AAMI ST72:2011
- Hydroxyapatite coating characterization, as specified by FDA Guidance 510(k) Information Needed for Hydroxyapatite Coated Orthopedic Implants, in accordance with ASTM F1160-05:2011, ASTM F1044-05:2011, ASTM F1147-05:2011, ASTM F1926:2010 and ISO 13779-3:2008
No clinical tests were conducted to demonstrate substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3353 Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis.
(a)
Identification. A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 21, 2018
DePuy France S.A.S. % Melissa Cook Regulatory Affairs Specialist DePuv Orthopaedics. Inc. 700 Orthopaedic Dr. Warsaw, Indiana 46582
Re: K173960
Trade/Device Name: DePuy Corail AMT Hip Prosthesis Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: Class II Product Code: LZO. MEH. KWL. KWY Dated: August 23, 2018 Received: August 24, 2018
Dear Melissa Cook:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Daniel S. Ramsey -S 2018.09.21 12:01:54 -04'00'
For Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K173960
Device Name
DePuy Corail AMT Hip Prosthesis
Indications for Use (Describe)
Total hip replacement or hip arthroplasty is indicated in the following conditions:
-
- A severely painful and/or disabled joint from osteoarthritis, traumatoid arthritis, or congenital hip dysplasia.
-
- Avascular necrosis of the femoral head.
-
- Acute traumatic fracture of the femoral head or neck.
-
- Failed previous hip surgery including joint reconstruction, arthrodesis, hemi-arthroplasty, surface replacement arthroplasty, or total hip replacement.
-
- Certain cases of ankylosis.
Partial hip replacement or hip hemi-arthroplasty is indicated in the following conditions:
-
- Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation.
-
- Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation.
-
- Avascular necrosis of the femoral head.
-
- Non-union of femoral neck fractures.
-
- Certain high subcapital and femoral neck fractures in the elderly.
-
- Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement.
-
- Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemiarthroplasty.
HA coated stems of the Corail Hip System are indicated for cementless use only.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
(As required by 21 CFR 807.92)
| Submitter Information | |
|---|---|
| Name | DePuy (Ireland) |
| Address | Loughberg |
| Ringaskiddy | |
| Cork, Ireland | |
| Phone number | 353 21 491 400 |
| Fax number | |
| Establishment Registration | |
| Number | 9616671 |
| Name of contact person | Melissa Cook |
| Date prepared | 23 August 2018 |
| Name of device | |
| Trade or proprietary name | DePuy Corail AMT Hip Prosthesis |
| Common or usual name | Uncemented hip prosthesis |
| Classification name | Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous |
| uncemented prosthesis | |
| Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis | |
| Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented | |
| prosthesis | |
| Class | II |
| Classification panel | 87 Orthopedics |
| Regulation | 21 CFR 888.3353, 888.3360, 888.3390 |
| Product Code(s) | LZO, MEH, KWL, KWY |
| Legally marketed | |
| device(s) to which | |
| equivalence is claimed | DePuy Corail AMT Hip Prosthesis (K123991, cleared September 16, 2013) |
| Reason for 510(k) | |
| submission | Line extension – The subject devices represent hip stems with additional |
| sizes to allow surgeons more flexibility in the choice of stem sizes, neck | |
| angles, and neck offsets. | |
| Device description | The DePuy Corail AMT hip stems are manufactured from forged titanium |
| alloy (Ti6Al4V) and plasma-sprayed with a hydroxyapatite (HA) coating for | |
| bone fixation. The stem consists of a wide range of stem neck designs and | |
| sizes allowing an accurate anatomical match for each patient. Corail AMT | |
| stems are available with or without a collar, with various neck angles, and | |
| with various neck offsets. The stems are compatible with both unipolar and | |
| bipolar heads intended for hip hemi-arthroplasty and with modular femoral | |
| heads intended for total hip arthroplasty. | |
| Intended use of the | |
| device | Total hip arthroplasty and hemi-hip arthroplasty |
| Indications for use | Total hip replacement or hip arthroplasty is indicated in the following |
| conditions: |
- A severely painful and/or disabled joint from osteoarthritis,
traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia. - Avascular necrosis of the femoral head.
- Acute traumatic fracture of the femoral head or neck.
- Failed previous hip surgery including joint reconstruction, internal
fixation, arthrodesis, hemi-arthroplasty, surface replacement
arthroplasty, or total hip replacement. - Certain cases of ankyloses.
Partial hip replacement or hip hemi-arthroplasty is indicated in the
following conditions:
- Acute fracture of the femoral head or neck that cannot be
appropriately reduced and treated with internal fixation. - Fracture dislocation of the hip that cannot be appropriately reduced
and treated with internal fixation. - Avascular necrosis of the femoral head.
- Non-union of femoral neck fractures.
- Certain high subcapital and femoral neck fractures in the elderly.
- Degenerative arthritis involving only the femoral head in which the
acetabulum does not require replacement. - Pathology involving only the femoral head/neck and/or proximal
femur that can be adequately treated by hip hemi-arthroplasty.
HA coated stems of the Corail Hip system are indicated for cementless use
only. |
4
5
SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE PREDICATE DEVICE
| Characteristics | Subject Device:
DePuy Corail AMT
Hip Prosthesis | Predicate Device:
DePuy Corail AMT
Hip Prosthesis
(K123991) | Reference Device:
DePuy Corail Hip
System, Revision Stem
(K093736) |
|-----------------|-------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Intended Use | Total Hip Arthroplasty,
Hemi-Hip Arthroplasty | Same | Total Hip Arthroplasty |
| Material | Ti6Al4V with plasma
sprayed HA coating | Same | Same |
| Fixation | Uncemented | Same | Same |
| Stem Size | 8, 9, 10, 11, 12, 13, 14,
15, 16, 18, 20 | Same | 10, 11, 12, 13, 14, 15,
16, 18, 20 |
| Neck Angle | 125° and 135° | Same | 135° |
| Neck Offset | Low, Standard, High | Standard, High | Standard, High |
| Collar | Collared, Collarless | Same | Collared |
| Sterile Method | Gamma | Same | Same |
| Packaging | Double PETG blister
with Tyvek peel lid | Same | Same |
| Shelf Life | 10 years | Same | Same |
PERFORMANCE DATA
SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE
- Neck fatigue testing in accordance with ISO 7206-6:1992 ●
- . Distal fatigue testing in accordance with ISO 7206-4:2010
- . Validation of taper dimension
- o Validation of taper to head and neck to head dimension
- Range of motion in accordance with ISO 21535:2007 ●
- Pyrogenicity testing using the Bacterial Endotoxin Testing (BET) method as specified in ANSI/AAMI ST72:2011
- Hydroxyapatite coating characterization, as specified by FDA Guidance 510(k) Information Needed for Hydroxyapatite Coated Orthopedic Implants, in accordance with ASTM F1160-05:2011, ASTM F1044-05:2011, ASTM F1147-05:2011, ASTM F1926:2010 and ISO 13779-3:2008
6
SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION
No clinical tests were conducted to demonstrate substantial equivalence.
CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA
The subject DePuy Corail AMT hip stems are substantially equivalent to the predicate DePuy Corail AMT hip stems.